Login to Your Account



U.S. NEWS
Getting tougher on dispensaries?

Advances made during the last five to seven years in cannabis-based therapies equal about 50 years' worth of the same in the pharmaceutical industry overall, George Scorsis, CEO of Liberty Health Sciences Inc., told BioWorld. Federal legislation to enable more experiments with marijuana will keep the pace brisk, along with work by the likes of GW Pharmaceuticals plc.

Despite the growing public health threats of pandemics, disastrous weather events and bioterrorism, the U.S. annually spends about half of what it costs to build an aircraft carrier on developing medical countermeasures, maintaining a stockpile of just-in-case diagnostics and treatments, and preparing and responding to threats that materialize around the world.

Ultragenyx Pharmaceutical Inc. and partner Kyowa Hakko Kirin Co. Ltd. (KHK) have won FDA approval for Crysvita (burosumab), making it the first U.S.-approved treatment for X-linked hypophosphatemia (XLH), a rare, inherited form of rickets. The chronic progressive musculoskeletal disorder is estimated to affect about 3,000 children and 9,000 adults in the U.S.

More U.S. Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: